Latest filing published 27 Mar 2026 for 지투지바이오, €28k.
Filing timeline
BuySaleInsider track record
No signal scores available.
Closed purchases
Not enough history yet: 1 closed purchase, at least 2 are needed.
Purchases by company
Since each purchase
- -38.9%Entry ₩71,900 · Close 06 Oct 2026 ₩43,900
- -25.6%Entry ₩89,200 · Close at T+90 ₩66,400
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
전교중: trading record in brief
전교중 (chief executive) discloses dealings in 지투지바이오 to DART (FSS). The record holds 3 filings, for trades running from 6 November 2025 to 27 March 2026.
No open-market sale appears; the market trades are 3 purchases worth €28k. No amount is published for 2 filings, which the totals therefore leave out. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Since January 2026: 2 purchases and no sales on the market.
The latest filing, published on 27 March 2026, reports an open-market purchase of €28k in 지투지바이오. These figures are compiled from regulatory filings published by DART (FSS). They describe what insiders did and are not a recommendation.
Companies and markets linked to 전교중
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 670 shares@ ₩74,000.000.0067% mcap100.0% of flowShareKRXDART:20260327000295Canonical exit: 25 Jun 2026 (T+90)
- ShareKRXDART:20260213002297Canonical exit: 7 May 2026 (T+90)
- 23,080 sharesShareKRXDART:20251106000289Canonical exit: 4 Feb 2026 (T+90)
3 of 3 declarations